· Form D filing · Baseline
Reported sold as filed: $1,200,000 · Offering amount as filed: $3,000,000
SEC source checked 29 Oct 2026. This is the issuer’s historical filing, not a current valuation.
View original evidence ↗BIOVENTRIX, INC.
On its website, the company describes its work as “Revivent Therapy is an investigational cardiac remodeling technique performed by a cardiothoracic surgeon under general anesthesia. It is designed to treat patients with heart failure…”.
- Industry
- Biotechnology
- Tracked VC backers
- 0
Tracking coverage and points
Tracking coverage
Some source history is available; coverage remains limited.
- Momentum +1 · Limited coverage
- The latest public index does not report a rank for this company.Index checked:
- Fundraising +2 · Limited coverage
- Verified filings recorded. Existing baseline history earns no points.SEC source checked:
- New VC +3 · Awaiting data
- No verified dated source evidence recorded.
- Completed exit +10 · Limited coverage
- Homepage checked. Exit news coverage is not established.Homepage checked:
Coverage describes public evidence. Points require a qualifying milestone after your pick.
Publicly documented VC backing
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
No tracked VC backing is recorded.